Zydus Lifesciences Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 11 Aug 2026

Company page: Zydus Lifesciences share price, financials & guidance record

Zydus Lifesciences reported a strong start to FY27 with robust revenue growth and healthy EBITDA margins. The company saw broad-based growth across its key segments, particularly in India branded formulations and international markets. Strategic investments in innovation, biosimilars, and acquisitions like Assertio Holdings are expected to drive future growth, despite some near-term impacts on costs and margins.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 11.0%, net profit down 11.7% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	2,621	2,516	5,820	2,588	2,871 +10%	2,284 −9%	3,741 −36%	2,872 +11%
Expenses	1,678	1,867	2,047	2,003	1,719	2,085	1,752	2,285
EBITDA	942	648	3,773	585	1,152 +22%	199 −69%	1,989 −47%	587 +0%
Margin	36%	26%	65%	23%	40%	9%	53%	20%
Other income	327	78	185	157	542	414	388	124
Interest	96	97	155	138	114	116	116	103
Depreciation	134	132	128	130	136	144	151	152
Profit before tax	1,039	497	3,675	475	1,444 +39%	352 −29%	2,111 −43%	456 −4%
Tax rate	24%	5%	23%	19%	20%	16%	18%	25%
Net profit	790	471	2,814	385	1,157 +46%	296 −37%	1,722 −39%	340 −12%
EPS	7.85	4.68	27.96	3.82	11.49	2.95	17.11	3.40

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls